{"id":"5aa9b979fe25","type":"article","url":"https://hartvaat.nl/2025/11/18/monocyten-hun-verdiende-erkenning-geven-cd47-sirp-herkadert-allograaftstoting/","title":"Monocyten hun verdiende erkenning geven: CD47-SIRPα herkadert allograaftstoting","title_en":"Giving monocytes their due: how CD47–SIRP-α reframes allograft rejection","category":"chronische nierziekte","category_label":"Nierziekte","professions":["internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)00877-4/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)00877-4/fulltext","authors":["Lennie Messager","Baptiste Lamarthée"],"significance":5,"published":"2025-11-18","source_date":"2025-11-18","image":"","kennis":[],"congress":"","summary_en":"This commentary discusses how the CD47-SIRPa axis reframes the understanding of monocyte-mediated allograft rejection. Despite decades of innovation targeting adaptive immunity, long-term graft survival has stagnated, highlighting the overlooked role of innate immune mechanisms in transplant rejection.","created":"2026-07-03T10:25:42Z","updated":"2026-07-03T13:25:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Ondanks decennia innovatie in adaptieve immunotherapie stagneert de langetermijn-graftoverleving. Dit commentaar bespreekt hoe de CD47-SIRPα-as de rol van monocyten bij allograaftstoting herkadert.","abstract_original":"Despite decades of therapeutic innovation targeting adaptive immunity, such as the development of calcineurin inhibitors and B-cell–depleting agents, like rituximab, long-term graft survival rates have stagnated, with nearly half of allografts failing within 10 years. This enduring challenge underscores a critical oversight in transplant immunology: the predominant focus on adaptive immune responses has largely neglected the role of innate immunity in graft rejection. Historically, rejection was attributed to T- and B-cell recognition of donor major histocompatibility complex (human leukocyte antigen [HLA]) molecules, relegating innate immune cells to a secondary role."}